StocktoriaAlzamend Neuro, Inc. ALZN
Nasdaq · XNAS · stock · Pharmaceutical Preparations
Chart by TradingView
1/9
Piotroski F — financial health
—
Altman Z″ — distress risk
—
Dividend payout · no dividend
Financials & ratios (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Financials | |||||
| Operating income | -$4.5M | -$9.9M | -$14.9M | -$12.3M | -$5.0M |
| Net income | -$4.5M | -$9.9M | -$14.9M | -$12.4M | -$5.0M |
| Operating cash flow | -$6.6M | -$8.3M | -$8.9M | -$6.6M | -$2.7M |
| Total assets | $4.6M | $631,588 | $5.9M | $14.5M | $2.9M |
| Total liabilities | $634,761 | $3.2M | $2.9M | $1.2M | $899,643 |
| Shareholders' equity | $4.0M | -$2.6M | $3.0M | $13.4M | $2.0M |
| Ratios | |||||
| Return on assets | -98.1% | -1575.0% | -251.5% | -85.2% | -173.3% |
| Return on equity | -113.8% | 383.5% | -488.5% | -92.6% | -250.7% |
| Current ratio | — | — | 2.03 | 12.37 | 3.24 |
Why these scores methodology →
Piotroski F-score: 1/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: n/a
Not applicable (financials/insurer or missing inputs).
Sector peers
VFS · TM · HMC · SONY · AAPL · XOM · all Manufacturing →
Source: SEC EDGAR filings · CIK 0001677077 · as of 2025-04-30. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.